UAMS Graduates 931 New Health Care Professionals
The University of Arkansas for Medical Sciences (UAMS) awarded certificates and degrees today to 931 graduates of its five colleges and graduate school during its commencement ceremony at Verizon Arena in North Little Rock.
Diplomas were presented to 161 in the College of Medicine; 214 in the College of Nursing; 125 in the College of Pharmacy; 50 in the Fay W. Boozman College of Public Health; 124 in the Graduate School and 225 from the 21 academic programs that make up the College of Health Professions.
During commencement, degrees and certificates conferred include the doctor of philosophy, doctor of medicine, doctor of pharmacy, master of science, master of nursing science, bachelor of science in nursing, master of public health, doctor of public health, certificate in clinical and translational science, master of health services administration, post baccalaureate certificate in public health and a variety of degrees in allied health disciplines including certificates, associate and bachelor of science degrees, post-baccalaureate certificates, the master of imaging sciences and doctor of audiology.
Drug Trial Leads to First FDA-Approved Treatment for Castleman’s Disease
The first-ever treatment for a rare blood disorder called multicentric Castleman’s disease was approved recently by the Food and Drug Administration after drug trials headed by a researcher at the University of Arkansas for Medical Sciences (UAMS).
Frits van Rhee, M.D., Ph.D., the nation’s leading expert in Castleman’s disease, led the years-long study of siltuximab in conjunction with Horsham, Pa.-based Janssen Biotech Inc. The drug was approved April 23 under the trade name Sylvant for patients who are HIV negative and human herpes virus-8 negative.
“The approval of Sylvant gives physicians a long-awaited treatment option for a group of patients who have been suffering with this chronic, serious and debilitating disease,” said van Rhee, a UAMS College of Medicine professor and director of developmental and translational medicine at UAMS. He also holds the Charles & Clydene Scharlau Chair for Hematological Malignancies Research.